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Abstract: Serum parameters as indicators for the efﬁ  cacy of therapeutic drugs are currently in the focus of intensive 
research. The induction of certain cytokines (or cytokine patterns) is known to be related to the status of the immune 
response e.g. in regulating the TH1/TH2 balance. Regarding their potential value as surrogate parameters in clinical 
trials and subsequently for the assignment of treatment efﬁ  cacy, the accurate and reliable determination of cytokines 
in patient serum is mandatory. Because serum samples are precious and limited, test methods—like the xMAP 
multiplex technology—that allow for the simultaneous determination of a variety of cytokines from only a small 
sample aliquot, can offer great advantages.
We here have compared multiplex kits from three different manufactures and found striking differences upon standardizing 
using WHO standards for selected cytokines. We therefore extended our xMAP multiplex measurements investigations to 
an ex-vivo situation by testing serum samples and found that the cytokine amounts measured was critically inﬂ  uenced by 
the actual kit used. The presented data indicate that statements regarding the quantitive determination of cytokines—and 
therefore their use as biomarkers—in serum samples have to be interpreted with caution.
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Introduction
For the investigation of cytokines involved in immune responses, multiplex kits have been shown to 
be of particular value (Jiang et al. 2003; Lagrelius et al. 2006; Panelli et al. 2004; Kircheis et al. 2006). 
One reason for this is that cytokine patterns rather than single cytokines have a pivotal importance in 
deﬁ  ning the balance between e.g. activation versus tolerization, or TH1 versus TH2 responses (Prabhakar 
et al. 2004; Kircheis et al. 1998) or in the angiogenesis process (Piperi et al. 2005). Although multiplex 
kits are usually more expensive than in-house designed assays, they are convenient because they allow 
performing a multi-parameter analysis within a short time period using only minute amounts of precious 
serum samples (Hildesheim et al. 2003; DeJager et al. 2003; Giavedoni, 2005). In many research pub-
lications the use of such kits is only brieﬂ  y described in the material and methods section using state-
ments such as: “… determined plasma concentration of cytokines, including IL1β, IL6 and TNFα, using 
a mouse Luminex kit …” (Cai et al. 2005). In contrast in-house designed assays usually require a detailed 
description and therefore the quality can be—at least in part—judged based on the supplied method 
description.
The vaccine-mediated induction of certain cytokines by active anti-cancer immuntherapy may be a 
valuable predictor for the subsequent treatment efﬁ  cacy (for review see Dranoff, 2004). For example, 
TNFα is selectively cytotoxic to a variety of transformed cells and many actions of TNFα occur in 
combination with other cytokines as part of the cytokine network (Ruddle, 1992). IFNγ is involved 
in nearly all phases of immune responses including activation, growth and differentiation of T-cells, 
B-cells, macrophages, and NK cells. Additionally, IFNγ enhances MHC expression on antigen-presenting 228
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cells (Schiller et al. 1990). IL-2 and IL-4 are 
representative cytokines involved in T-cell activa-
tion, and the balance between Th1 and Th2 is 
largely determined by the balance between IFNγ 
and IL-4, respectively. Furthermore, the cytokines 
IL-2, IL-4, TNFα and IFNγ have been shown to 
inhibit tumor-induced angiogenesis in some animal 
models by inhibition of tumor stroma formation 
(Prabhakar et al. 2004; Blankenstein, 2005). In 
order for such cytokines to be used as surrogate 
clinical parameters, their accurate determination 
is mandatory because usually threshold concentra-
tions have to be reached for effective cytokine 
actions (Kircheis et al. 1992; Schmidt et al. 1995; 
Yang et al. 2004).
To minimize sample consumption during cyto-
kine determination, xMAP multiplex technology 
was applied which uses spectrally addressable 
polystyrene beads as array elements to enable the 
simultaneous analysis of up to one-hundred ana-
lytes in only a few microliters of sample. By cou-
pling the cytokine speciﬁ  c capture antibody to a 
speciﬁ  c bead in combination with a phycoerythrin 
labeled cytokine speciﬁ  c detection antibody, the 
amounts of cytokines present in samples can be 
determined.
To get insight into the accuracy of commercially 
available test systems for the detection of INFγ, 
TNFα, IL-2 and IL-4, we have compared kits from 
different manufacturers, i.e. Biosource, Linco and 
Upstate by testing them according to the protocol 
provided by each manufacturer. INFγ, TNFα, IL-2 
and IL-4 were chosen because they represent a 
well-documented panel of cytokines involved in 
regulating the immune system (Ruddle, 1992; 
Schiller et al. 1990; Blankenstein, 2005). Our 
experiments included the comparison of the three 
kit standards by measuring them with each kit (i.e. 
Biosource, Linco and Upstate, respectively) and 
the testing of the correlation of the kit standard 
with the WHO standard.
As an example, we tested the xMAP multiplex 
approach for measurement of cytokine release of 
Rhesus monkeys before and after immunization 
with the multi-component cancer vaccine Vela402 
(previously IGN402). This vaccine has been shown 
to induce a signiﬁ  cant IgG response against carrier 
protein and the attached carbohydrate epitopes 
(Kircheis et al. 2006; Kircheis et al. 2007).
Generally, our data demonstrate that the deter-
mination of the amount of various cytokines in 
serum samples using Luminex based multiplex 
technology is critically inﬂ  uenced by the actual kit 
used. In context of the increasing use of multi-
plexed kits in biomedical research and their poten-
tial application for surrogate markers in clinical 
trials, the results of the present study indicate that 
such data have to be interpreted with caution. 
Therefore, although the multiplex technology 
offers important advantages like the use of limited 
sample volume, the possibility of measuring a 
broader spectrum of biomarkers, reduced time and 
consumables costs and scalability (Ray et al. 2005), 
assay validation is of utmost importance for the 
acquisition of reliable data.
Material and Methods
WHO standards
Freeze dried recombinant human interferon gamma 
(IFNγ) reference (Cat. Nr. #Gxg01-902-535) was 
kindly provided by the National Institute of Allergy 
and Infectious Diseases (NIAID) reference reagent 
deposit operated by KamTek, MD, U.S.A. Freeze 
dried human natural tumour necrosis alpha (TNFα) 
reference (code 88/786), freeze dried human 
recombinant interleukin-4 (IL4) reference (code 
88/656) and freeze dried human recombinant inter-
leukin-2 (IL2) reference (code 86/504) were kindly 
provided by the National Institute for Biological 
Standards and Control (NIBSC), Hertfordshire, 
U.K. Each standard was reconstituted according 
to the accompanying NIAID or NIBSC datasheet, 
aliquoted and stored at −80 °C. One aliquot was 
used for each assay—left over material from the 
experiments was discarded.
Quantitation of cytokine levels 
using xMAP technology
For cytokine determination, multiplex kits from 
Upstate (NY, U.S.A.), Biosource (Invitrogen, CA, 
U.S.A.) and Linco (MI, U.S.A.) were purchased and 
used according to the manufactures protocol. Brieﬂ  y, 
the beads provided within each kit were incubated 
with buffer, kit standards or serum samples in a 
96-well plate at room temperature. All incubations 
were performed at room temperature in the dark 
(covered with aluminum foil) on a plate shaker. 
Millipore multiscreen plates (Cat. Nr. #MABVN12) 
were used together with the Millipore ﬁ  ltration sys-
tem (Cat. Nr. #MAVM0960R)— the vacuum suction 
during each washing step was set to ~200μl/5 seconds. 229
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For measurement, a Luminex IS 100 equipment was 
used. One-hundred events per bead region were 
counted (sample volume 50 μl) with the Double 
Discriminator gate set to 8000–15000. Data were 
evaluated applying a 5-parameter logistic curve ﬁ  t 
using the StarStation software version 1.1. All 
specimens were tested in duplicates and the results 
are reported as the mean. The standards curve was 
generated by a 5-parameter logistic ﬁ  t.
Protocol: Upstate kit
According to ‘Multiple Cytokine detection protocol 
B’ the lyophilized standards (from 100 μl PBS, pH 
7.4 with 10% BSA, 5% Trehalose, and 0.05% NaN3) 
were resuspended in 1 ml Serum Standard Diluent 
(proprietary formulation of animal protein and sera 
buffered with phosphate containing 0.1% NaN3). 
Brieﬂ  y, to the pre-wetted wells, 50 μl of sample or 
standard was added followed by 25 μl sonicated bead 
solution. After incubating 2 hours, the wells were 
washed once with 50 μl Assay Buffer (PBS, 0.05% 
NaN3, 0.05% Tween-20, 1% BSA, pH 7.4) and the 
beads were resuspended in 75 μl Assay Buffer. Then, 
25 μl Beadlyte biotinylated anti-human multi-
cytokine antibodies were added to each well and 
incubated for 90 minutes. Then, 25 μl of diluted 
Streptavidin-Phycoerithrin were added to each well, 
vortexed and incubated for 30 minutes. Afterwards 
25 μl Stop Solution were added, vortexed and 
incubated for 5 minutes. The liquid was removed by 
vacuum suction and the samples were resuspended 
in 125 μl Assay Buffer. The plate was gently 
vortexed, incubated on a shaker for 60 seconds and 
read on a Luminex IS 100 instrument.
Protocol: Linco kit
All reagents were brought to room temperature. 
Standards were reconstituted with deionized water 
and further diluted with Assay Buffer (50 mM PBS, 
25 mM EDTA, 0.08% NaN3, 0.05% Tween-20, 1% 
BSA, pH 7.4). To the pre-wetted wells, 25 μl of 
Assay Buffer were added, followed by 25 μl 
sample (to the wells representing background, 
standards and control, 25 μl Serum Matrix is 
added) and 25 μl beads. After incubation for 
1 hour, the ﬂ  uid was removed by vacuum suction. 
The plate was washed twice with Wash Buffer and 
remaining liquid from the bottom of the plate was 
removed by blotting the plate on paper towels. 
Then, 25 μl of Detection Antibody Cocktail was 
added and incubated for 30 minutes. After washing 
twice as described in the previous step, 100 μl 
Sheat Fluid was added to all wells and beads were 
resuspended by shaking for 5 minutes. Afterwards 
the plate was measured.
Protocol: Biosource kit
To the pre-wetted wells, 25 μl antibody coated 
beads were added followed by 50 μl Incubation 
Buffer (proprietary formulation), 50 μl Dilution 
Buffer (proprietary formulation) and 50 μl serum 
sample (or spiked NHS). The standards were recon-
stituted and diluted in Assay Diluent (proprietary 
formulation). The plate was shaken for 2 hours and 
after washing twice, 100 μl biotinylated detection 
antibody were added and incubated for 1 hours. 
After two further washing steps, 100 μl of Strepta-
vidin-Phycoerythrin were added and incubated for 
30 minutes. The plate was washed three times and 
100 μl Wash Buffer were added. The plate was then 
shaken for 30 seconds and measured.
Comparison of the kit standard 
to the WHO reference
Human serum containing cytokines was mimicked 
by spiking the WHO standards into normal human 
serum (NHS). To get insight into the recovery rate 
of the spiked WHO standard using the standard 
curve obtained with the standards provided with 
each individual kit, the following experimental 
set-up was applied:
(i)    for the Upstate kit, the Upstate cytokine stan-
dard was dissolved and diluted in Upstate 
Serum Standard Diluent (SSD) provided with 
the kit. The WHO standards were spiked into 
1 ml of NHS (= patient matrix mimic) and 
diluted further with SSD. The assay was per-
formed according to the Upstate protocol as 
described above.
(ii)    for the Linco Kit, the Linco cytokine standard 
were reconstituted with deionized water and 
further diluted with Assay Buffer. The WHO 
standards were spiked into 1 ml of NHS and 
diluted further with Assay Buffer. The assay 
was performed according to the Upstate pro-
tocol as described in above.
(iii)   for the Biosource Kit, the Biosource standard 
were reconstituted and diluted in Assay Dilu-
ent. The WHO standards were spiked into 1 ml 
of NHS and diluted further with Assay Buffer. 
The assay was performed according to the 
Upstate protocol as described above.230
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Cross-testing of kit standards and 
comparison to WHO reference 
standards
To get insight how well the three different kit 
standards correlate with each other and the WHO 
standard, the following experimental set-up was 
applied: as example for the Linco kit, the recon-
stituted standards from Linco, Upstate and Bio-
source, respectively, were diluted with Linco Assay 
Buffer according to their own (Upstate, Linco, and 
Biosource, respectively) kit manual. The WHO 
standards were spiked into, and further diluted 
with, the Linco Assay Buffer. The assay was per-
formed according to the Linco protocol.
In analogous experiments, the above outlined 
set-up was applied to the Upstate and the Biosource 
kit and the individual assay was subsequently 
performed according to the Upstate protocol and 
Biosource protocol.
Serum samples from rhesus monkeys
Safety, tolerability and immunogenicity of multiple 
subcutaneous injections of Vela402 were evaluated 
in vaccination studies in Rhesus monkeys. Vela402 
(previously IGN402) is a multi-component synthetic 
cancer vaccine containing SialylTn carbohydrate 
tumor-associated antigen epitopes coupled to a 
highly immunogenic protein carrier and formulated 
in a highly immunogenic formulation with QS-21 
adjuvant (Kircheis et al. 2006; Kircheis et al. 2007). 
The animal study was performed under controlled 
and documented conditions in accordance with 
animal health care standards at Biotest Ltd., 
Konarovice, Czech Republic. Healthy adult Rhesus 
monkeys, four animals per group, were vaccinated 
with four initial immunizations on days 1, 15, 29, 
and 57. Pre-sera and immune sera taken at day 43 
were analyzed for cytokines (IL-2, IL-4, TNFα, 
IFNγ) by xMAP Multiplex technology (Luminex) 
using the three kits (Biosource, Linco and Upstate) 
according to the manufacturer’s protocol.
Results
To determine the accuracy of the standards of each 
kit, we measured the standards provided with the 
respective kit, e.g. Linco standards (diluted in 
serum matrix diluent) in the Linco kit, and com-
pared them to WHO standards spiked into similarly 
diluted normal human serum (NHS) matrix from 
two healthy donors. As can be seen in Figure 1 the 
read-out obtained with the IL-2 standards provided 
by all kits were in accordance with the WHO stan-
dard. In contrast, the IL-4 standard from Linco was 
greatly (more than 1 log) underestimated in the 
Linco kit compared to the WHO standards (Fig. 1) 
which would result e.g. in a dramatic overestima-
tion of the IL-4 titers in serum. For TNFα, the 
Biosource standard was found to be underestimated 
in the Biosource kit (Fig. 1). The Linco TNFα 
standards performed slightly better than the WHO 
standard resulting in a slight underestimation of 
the TNFα serum content suggesting that the values 
measured are, in fact, higher. With the Upstate kit, 
the WHO calibration curve generated showed at 
its highest concentration a so-called “hook-effect” 
which is often observed in biological assays with 
samples at high serum concentration and which 
may be due to inhibitory factors found at high 
serum concentrations. Another explanation for the 
hook effect might be an ‘over-coating’ of the 
Upstate beads with the capture antibody. Finally, 
IFNγ measurements revealed a good alignment 
with the WHO and the Biosource standards, a slight 
underestimation of the Linco standards and good 
alignment with the WHO standard, and a “hook-
effect” at high concentrations, in the Upstate kit. 
The possibility that the isotype of the capture/
detection antibody pairs is responsible for the 
reported differences can be ruled out because for 
at least 3 cytokines (IL-2, TNFα and IFNγ) these 
isotypes are identical at least in two kits (Linco 
and Biosource kit—data for the Upstate kit were 
not available).
Next we determined how accurate each kit 
measures its own standards and the standards pro-
vided by the other kits as compared to the WHO 
standard (Fig. 2). Regarding IL-2, all standards 
were recovered equally well with the Biosource 
and the Upstate kit. In contrast, within the Linco 
kit, all standards were overestimated when com-
pared to Linco IL-2 standard. For IL-4, the Linco 
standard was greatly underestimated compared to 
the Biosource and the Upstate standards in all three 
assays. The TNFα standard from Linco was 
somewhat overestimated in the Biosource kit but 
reasonably quantiﬁ  ed with the other kits. In con-
trast, the Biosource standard was underestimated 
when measured in the Linco and the Upstate kit, 
respectively. Noteworthy, for IFNγ the WHO 
calibrator performed better than all other standards 
when measured with the Biosource and the Linco 
kit. With the Upstate kit, no differences between 231
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kit standards and WHO standards were found. In 
summary, the cross-testing of the three kit stan-
dards revealed that the Biosource standards worked 
excellently for IL-2 and IL-4 in all three kits but 
the TNFα and IFNγ the standards from Biosource 
were underestimated in the Linco and the Upstate 
kits. Of all standards tested, the Linco standards 
showed the largest deviations—even when tested 
in their own kit, only TNFα correlated with the 
WHO reference. In contrast, the Upstate standards 
performed equally well in all three kits and the 
obtained read-out always correlated with the WHO 
standard indicating that this kit is best suited for 
reliable cytokine determination.
We ﬁ  nally applied the three kits to “real serum 
sample” measurements, i.e. serum obtained from 
a vaccination study in Rhesus monkeys. The detec-
tion of systemic cytokine release after vaccination 
applying xMAP technology has been recently 
demonstrated by Kircheis et al. (2007). As shown 
in Figure 3, depending on the kit used, different 
amounts of released cytokines were detected after 
vaccination when compared to the corresponding 
pre-serum. For IL-2, the Linco kit identified 
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Figure 1. Standard comparison. Standards provided within each kit were diluted according to the protocol with matrix diluent. The WHO 
standards were spiked into two different normal human sera from healthy donors (designated “NHS1-WHO” and “NHS2-WHO”) and diluted 
with matrix diluent. Panels grouped ‘in line’ show the indicated cytokine determined with three different kits; panels grouped ‘in row’ show 
all cytokines determined with one kit.232
Nechansky et al
Biomarker Insights 2008:3 
Biosource: IL-2
1
10
100
1000
10000
1          10         100        1000     10000 1          10         100        1000     10000 1          10         100        1000     10000
1          10         100        1000     10000 1          10         100        1000     10000 1          10         100        1000     10000
1          10         100        1000     10000 1          10         100        1000     10000 1          10         100        1000     10000
1          10         100        1000     10000 1          10         100        1000     10000 1          10         100        1000     10000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Linco: IL-2
1
10
100
1000
10000
100000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Upstate: IL-2
1
10
100
1000
10000
100000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Biosource: IL-4
1
10
100
1000
10000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Linco: IL-4
1
10
100
1000
10000
100000
1000000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Upstate: IL-4
1
10
100
1000
10000
100000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Biosource: IFNγ
1
10
100
1000
10000
100000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Linco: IFNγ
1
10
100
1000
10000
100000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Upstate: IFNγ
1
10
100
1000
10000
100000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Linco: TNFα
1
10
100
1000
10000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Upstate: TNFα
1
10
100
1000
10000
100000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Biosource: TNFα
1
10
100
1000
10000
100000
pg/ml expected
p
g
/
m
l
 
m
e
a
s
u
r
e
d
Figure 2. Cross-testing of kit standards and comparison to WHO reference standards. Standards provided within the Upstate (blue triangles), 
Linco (green squares), Biosource (magenta circles) kit and WHO reference standards (black crosses) were diluted in assay buffer of one 
kit and measured according to the kit’s protocol.233
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individuals (ID) 2 and 4 with up to 100-fold 
increased cytokine levels after immunization. In 
contrast, with the Biosource these two samples 
were only weakly positive and with the Upstate kit 
only in ID 4 a response was detected (which was 
of the same magnitude as measured with the Linco 
kit). The differences between the various kits were 
particularly evident when comparing the IL-4 data: 
while for e.g. ID 4 all three kits detected a 
signiﬁ  cant increase after immunization, for ID 2 
only background values were measured with the 
Biosource and the Upstate kit whereas the Linco 
assay detected signiﬁ  cant amounts in ID 2 AND 
ID 4 following immunization. Elevated TNFα 
levels in the immune sera were identiﬁ  ed with the 
all three kits applied. For IFNγ, the Linco kit gave 
the highest read-out which was partly in agreement 
with the data generated using the Upstate kit which 
also identiﬁ  ed ID 2 AND ID 4 immune sera as 
positive—albeit at ~ 10-fold lower levels. In 
contrast, the Biosource kit did not detect IFNγ in 
ID 2 but (at marginal levels) in ID 4.
The obtained differences between the kits can 
not be explained by a difference in the assay 
sensitivity because the sensitivity of all three kits 
(as stated by the manufactures) lies roughly in 
same range (Table 1). A potential reason for the 
observed differences might be due to a different 
cross-reactivity of the different antibody pairs 
with the monkey serum and the human serum, 
respectively. Based on the extremely high 
homology of human and monkey INFγ, TNFα, 
IL-2 and IL-4 such cross-reactivity is expected to 
be neglectable.
Discussion
Prior to measurement of the induced cytokine 
levels of serum samples by xMAP multiplex tech-
nology, the performance of kits from three differ-
ent manufactors (Linco, Biosource and Upstate, 
respectively) was evaluated. The three kits were 
tested according to the protocol provided with each 
kit. Our results revealed striking differences 
questioning the usefulness of these kits regarding 
the accurate and reliable determination of the 
cytokine amounts. In detail, we found a substantial 
discordance of the supplied standards with the 
respective WHO standards. In particular, the IL-4 
standard provided by the Linco kit was signiﬁ  -
cantly underestimated in all three kits (including 
the Linco kit) which would result in an overestima-
tion of the IL-4 titers of measured samples when 
calibrated using the IL-4 standard curve. Further-
more, the Linco IL-2 standard was underestimated 
in the Linco kit and Biosource TNFα standard was 
underestimated in the Biosource kit.
In this context, Prabhakar and colleagues found 
that—when measuring human serum samples with 
a Linco kit—only the recovery for TNFα was 
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Figure 3. Kit comparison: Serum samples from Rhesus monkeys before 
and after immunization with Vela402 conjugate vaccine were analyzed 
for IL-2, IL-4, IFNγ and TNFα using kits from three manufactures. Pre-
serum levels are shown as light grey bars, immune serum levels are 
shown in dark grey. Asterisks: sample not measured. The Mean values 
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within the expected range but recoveries of IL-2, 
IL-4, IL-5, IL-10 and IFNγ remained low and 
showed high variability. They also reached the 
conclusion that ‘real world’ assay performance has 
to be evaluated thoroughly when trying to compare 
the results of different methods. Furthermore, Lash 
et al. (2006) reported that even the results obtained 
with two multiplex sandwich ELISA’s and a bead 
based multiplex assay can not be compared.
Hildesheim et al. have reported that using the 
Linco kit for IL-6 and IL-8 determination resulted 
in invariably high read-outs, and for IL-4 amounts 
extremely low values were measured—these 
ﬁ  ndings led to the exclusion of these cytokines from 
evaluation. Khan and coworkers have compared two 
kits from different manufacturers, i.e. Biosource and 
Linco, for IFNγ and TNFα detection in sera of 
healthy subjects after endotoxin injection. This study 
also reported higher levels of TNFα using the Bio-
source kit compared to the Linco kit and highlighted 
false positive results. Because determination of 
cytokines using conventional ELISA kits from com-
mercial sources revealed no signiﬁ  cant difference 
for TNFα levels (Aziz et al. 1999) the possibility 
exits that xMAP based multiplex technology has not 
been fully standardized yet.
Our data extend these investigations to a pre-
clinical vaccination study where the induction of 
cytokines (like IL-2, IL-4, IFNγ, and TNFα)—if 
measured accurately—might serve as surrogate 
markers for the assessment of therapeutic efﬁ  cacy 
(Panelli et  al. 2004; Schiller et  al. 1990; 
Blankenstein, 2005; Kircheis et al. 1992; Schmidt 
et al. 1995; Yang et al. 2004). Serum samples 
obtained from Rhesus monkeys before and after 
immunization with the highly immunogenic 
vaccine formulation Vela402 were used for 
cytokine determination. The data from the cross-
over experiments with standards from different kits 
compared to WHO standard together with the data 
obtained from the analysis of serum samples 
indicated that among the different kits tested, the 
kit from Upstate appeared to give the most reliable 
data, since it showed the most overlapping results 
with the other two kits tested. In contrast, the Linco 
kit—although possibly providing highest sensitivity, 
tends to provide overestimated values due to the 
underestimation of its own standard compared to 
the WHO and the standards of the other kits. 
Biosource showed generally the lowest values for 
cytokine release among the three kits. Therefore, 
in all our following pre-clinical studies concerning 
the Vela402 project cytokine release was measured 
using the Upstate kit.
Our results suggest that the performance of (at 
least three) available multiplex kits differs and that 
therefore initial kit testing prior to a series of 
measurements might improve the quality of the 
data. For the measurement of samples from clini-
cal studies we highly recommend the validation 
of the particular assay (which has to be speciﬁ  ed 
in the clinical study protocol) according to Inter-
national Conference of Harmonization (ICH) 
guidelines. Such validation guarantees that the 
obtained data are valid and can be reported to 
authorities (especially when the standard curve 
was recorded using an international—and there-
fore accepted—standard). Differences due to dif-
ferent kit or reagent lots which are one of the main 
sources for unexpected results can be identiﬁ  ed 
applying a validated assay.
This validation approach has been performed 
for the simultaneous measurement of ﬁ  ve cytokines 
using 2000 serum samples from patients with 
sepsis (Ray et al. 2005). The result showed that for 
TNFα the number of freeze/thaw cycles must 
not exceed two—otherwise the recovery is 
decreasing. The serum samples that were used in 
our study were frozen/thawed only once. Thus the 
appropriate storage conditions should guarantee 
analyte stability and therefore altered analyte(s) 
are not the explanation for the observed discrepan-
cies between the kits used. Additional critical 
parameters, like appropriate negative control 
matrices, have to be identiﬁ  ed by a risk assessment 
procedure that should be based on the known 
pitfalls of multiplexing described in literature 
(Whiteside et al. 2002) and the speciﬁ  c patient 
population studied. Initial experiments have to 
focus on assessing the inﬂ  uence of serum compo-
nents (e.g. immunoglobulins, lipids or rheumatoid 
Table 1. Assay sensitivity (pg/ml). Sensitivity is 
defined according to the Linco datasheet as the 
“minimum detectable concentration” and within the 
Upstate datasheet as “two standard deviations above 
the mean MFI of 20 replicates of the zero standard”. 
No deﬁ  nition is given within the Biosource datasheet.
 Upstate  Biosource  Linco
IL-2 1  6 0.9
IL-4 1  5 4
TNFα 1  10 3.3
IFNγ 16  5 1.3235
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factors) and the sample dilution on the recovery 
rate of the various cytokines. It should be noted 
that, whereas information regarding the antibody 
isotypes used within the various kits was partly 
available, no information was given by the manu-
facturers regarding the speciﬁ  c clones used. This 
information would be helpful because the clone 
speciﬁ  c antibodies might show differing avidity/
affinity for the antigens, a fact which could 
inﬂ  uence the quantitation.
In summary, we wish to point out that performing 
an assay “according to the manufacturer’s instruc-
tions” does not necessarily guarantee reliable 
quantitative data—and even the collection of 
qualitative data may be questionable. Especially, 
in the light of the increasing interest in potential 
serum surrogate parameters indicative for clinical 
efﬁ  cacy (Saheb et al. 2007), the results of the 
present study indicate that cytokine level measure-
ments in human serum have to be interpreted with 
great caution, especially with respect to the 
absolute cytokine amounts reported.
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